Skip to main content
Clinical Trials/NCT03172338
NCT03172338
Unknown
Not Applicable

Smart - Systems Medicine of Heart Failure

German Heart Institute1 site in 1 country60 target enrollmentJune 2, 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Aortic Valve Disease
Sponsor
German Heart Institute
Enrollment
60
Locations
1
Primary Endpoint
Hypertrophy
Last Updated
8 years ago

Overview

Brief Summary

The onset and course of heart failure (HF) is triggered by a complex regulatory network that includes stressors (pressure overload by individual anatomic hemodynamic settings), intrinsic (genes), environmental (regulating epigenetics), and modifying factors (such as hor-mones and the immune system). SMART aims to establish individualized strategies for the prevention and management of HF by early detection of the physiological, genomic, proteo-mic and hemodynamic mechanisms that lead from onecommon cause of ventricular dysfunction (pressure overload) to maladaptive remodelling and irreversible HF. To cope with the complexity of HF, SMART will interrelate models describing the interplay between ge-nome, proteome and cell function, regulating hormones, tissue composition and hemody-namic whole organ function up to a whole body description of a patient and patient cohorts. The ultimate goal is to demonstrate proof-of-concept tools for predicting disease evolution and efficacy of treatment in a given patient. To achieve this task SMART will apply

  • A modelling framework that couples multi-scale mechanistic models with in-depth genome/proteome, cell physiology and whole organ (biomechanical and fluid dynamic) models
  • Subsequently, investigate methods validity and relevance for "quantitative prediction" of treatment outcome in a clinical proof-of-concept trial (demonstrator) of patients with aortic valve desieases.
Registry
clinicaltrials.gov
Start Date
June 2, 2015
End Date
February 28, 2018
Last Updated
8 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
German Heart Institute
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Aortic Valve Stenosis

Exclusion Criteria

  • coronary heart disease

Outcomes

Primary Outcomes

Hypertrophy

Time Frame: 3 months

Muscle Mass and Fibrosis

Study Sites (1)

Loading locations...

Similar Trials